Non-antimicrobial activities of macrolides

International Journal of Antimicrobial Agents

Volumn 18, Issue SUPPL.1, 2001, Pages 89-91

  Williams, J D ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Anticancer activity; Gastrointestinal motility; Immunomodulation; Macrolides; Pharmacology

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; MACROLIDE;

DRUG EFFECT; GASTROINTESTINAL MOTILITY; HUMAN; IMMUNOLOGY; REVIEW;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; IMMUNOLOGIC FACTORS; MACROLIDES;

EID: 4243936277     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0924-8579(01)00395-8     Document Type: Article

References (20)

1. Zara GP, Thompson HH, Pilot MA, Richie HD. Effects of erythromycin on gastrointestinal activity. J Antimicrob Chemother 1985;16(Suppl. A):175-9.
2. Pilot MA, Williams JD. Gastrointestinal effects of macrolides. In: Bryskier AJ, Butzler J-P, Neu HC, Tulkens PM, editors. Macrolides: Chemistry, Pharmacology and Clinical Uses. Paris: Arnette Blackwell, 1993:659-71.
3. Itoh Z, Suzuki T, Nakaya M, Inoue M, Mitsuhashi S. Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut. Antimicrob Agents Chemother 1984;26:863-9.
4. Tomomasa T, Kuroume T, Arai H, Wakabayashi K, Itoh Z. Erythromycin induces migrating motor complex in human gastrointestinal tract. Dig Dis Sci 1986;31:157-61.
5. Inatomi N, Satoh H, Maki Y, Hashimoto N, Itoh Z, Omura S. An erythromycin derivative, EM-523, induces motilin-like gastrointestinal motility in dogs. J Pharmacol Exp Ther 1989;251:707-12.
6. Kawamura O, Sekiguchi T, Itoh Z, Omura S. Effect of erythromycin derivative EM523L on human interdigestive gastrointestinal tract. Dig Dis Sci 1993;38:1026-31.
7. Verhagen MA, Samsom M, Maes B, et al. Effects of a new motilide, ABT-229, on gastric emptying and postprandial antroduodenal motility in healthy volunteers. Aliment Pharmacol Ther 1997;11:1077-86.
8. Itkin IH, Menzel ML. The use of macrolide antibiotic substances in the treatment of asthma. J Allergy 1970;45:146-62.
9. Cabanieu G. The value and the tolerance of troleandomycin in the long-term treatment of asthma and chronic bronchitis. Quad Antibiot 1975; 110-21.
10. Taub SJ. Steroid use reduced in asthma. Eye Ear Nose Throat Mon 1974;53:297-8.
11. Baldridge CW, Gerard RW. The extra respiration of phagocytosis. Am J Physiol 1933;102:235-6.
12. Suez D, Szefler SJ. Excessive accumulation of mucus in children with asthma: a potential role for erythromycin? A case discussion. J Allergy Clin Immunol 1986;77:330-4.
13. Mikami M. Clinical and pathophysiological significance of neutrophil elastase in sputum and the effect of erythromycin in chronic respiratory diseases. Nihon Kyobu Shikkan Gakkai Zasshi 1991;29:72-83.
14. Tamaoki J, Takeyama K, Yamawaki I, Kondo M, Konno K. Lipopolysaccharide-induced goblet cell hypersecretion in the guinea pig trachea: inhibition by macrolides. Am J Physiol 1997;272:15-9.
15. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997;155:2018-23.
16. Rhee CS, Majima Y, Arima S, et al. Effects of clarithromycin on Theological properties of nasal mucus in patients with chronic sinusitis. Ann Otol Rhinol Laryngol 2000;109:484-7.
17. Yanagihara K. Diffuse panbronchiolitis: pathophysiology and treatment mechanisms. Int J Antimicrob Agents 2001;18(Suppl. 1):83-7.
18. Wang L, Kitaichi K, Hui CS, et al. Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. Clin Exp Pharmacol Physiol 2000;27:587-93.
19. Hamada K, Mikasa K, Yunou Y, et al. Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer. Chemotherapy 2000;46:49-61.
20. Mikasa K, Sawaki M, Kita E, et al. Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin. Chemotherapy 1997;43:288-96.